These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 33061471)

  • 1. Drugs for Multiple Sclerosis Activate Natural Killer Cells: Do They Protect Against COVID-19 Infection?
    Al-Ani M; Elemam NM; Hundt JE; Maghazachi AA
    Infect Drug Resist; 2020; 13():3243-3254. PubMed ID: 33061471
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monomethyl fumarate augments NK cell lysis of tumor cells through degranulation and the upregulation of NKp46 and CD107a.
    Vego H; Sand KL; Høglund RA; Fallang LE; Gundersen G; Holmøy T; Maghazachi AA
    Cell Mol Immunol; 2016 Jan; 13(1):57-64. PubMed ID: 25435072
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drugs Used in the Treatment of Multiple Sclerosis During COVID-19 Pandemic: A Critical Viewpoint.
    Alborghetti M; Bellucci G; Gentile A; Calderoni C; Nicoletti F; Capra R; Salvetti M; Centonze D
    Curr Neuropharmacol; 2022; 20(1):107-125. PubMed ID: 33784961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glatiramer Acetate, Dimethyl Fumarate, and Monomethyl Fumarate Upregulate the Expression of CCR10 on the Surface of Natural Killer Cells and Enhance Their Chemotaxis and Cytotoxicity.
    Maghazachi AA; Sand KL; Al-Jaderi Z
    Front Immunol; 2016; 7():437. PubMed ID: 27807435
    [No Abstract]   [Full Text] [Related]  

  • 5. Utilization of Dimethyl Fumarate and Related Molecules for Treatment of Multiple Sclerosis, Cancer, and Other Diseases.
    Al-Jaderi Z; Maghazachi AA
    Front Immunol; 2016; 7():278. PubMed ID: 27499754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DPP4 and ACE2 in Diabetes and COVID-19: Therapeutic Targets for Cardiovascular Complications?
    Valencia I; Peiró C; Lorenzo Ó; Sánchez-Ferrer CF; Eckel J; Romacho T
    Front Pharmacol; 2020; 11():1161. PubMed ID: 32848769
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential Role of Peptide-Based Antiviral Therapy Against SARS-CoV-2 Infection.
    Maiti BK
    ACS Pharmacol Transl Sci; 2020 Aug; 3(4):783-785. PubMed ID: 32821885
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bracing NK cell based therapy to relegate pulmonary inflammation in COVID-19.
    Jeyaraman M; Muthu S; Bapat A; Jain R; Sushmitha ES; Gulati A; Channaiah Anudeep T; Dilip SJ; Jha NK; Kumar D; Kesari KK; Ojha S; Dholpuria S; Gupta G; Dureja H; Chellappan DK; Singh SK; Dua K; Jha SK
    Heliyon; 2021 Jul; 7(7):e07635. PubMed ID: 34312598
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Forest-bathing and physical activity as weapons against COVID-19: a review.
    Roviello V; Gilhen-Baker M; Vicidomini C; Roviello GN
    Environ Chem Lett; 2022; 20(1):131-140. PubMed ID: 34566548
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NK cells in COVID-19: protectors or opponents?
    Alrubayyi A
    Nat Rev Immunol; 2020 Sep; 20(9):520. PubMed ID: 32732951
    [No Abstract]   [Full Text] [Related]  

  • 11. B cell targeting therapies in MS patients during the SARS-CoV-2 pandemic - when immunosuppression meets infection?
    Mycko MP
    Neurol Neurochir Pol; 2020; 54(6):490-501. PubMed ID: 33073348
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent findings on the Coronavirus disease 2019 (COVID-19); immunopathogenesis and immunotherapeutics.
    Ebrahimi N; Aslani S; Babaie F; Hemmatzadeh M; Hosseinzadeh R; Joneidi Z; Mehdizadeh Tourzani Z; Pakravan N; Mohammadi H
    Int Immunopharmacol; 2020 Dec; 89(Pt B):107082. PubMed ID: 33068865
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vitamin D deficiency in association with endothelial dysfunction: Implications for patients with COVID-19.
    Zhang J; McCullough PA; Tecson KM
    Rev Cardiovasc Med; 2020 Sep; 21(3):339-344. PubMed ID: 33070539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of anti-osteoporosis treatments on the incidence of COVID-19 in patients with non-inflammatory rheumatic conditions.
    Blanch-Rubió J; Soldevila-Domenech N; Tío L; Llorente-Onaindia J; Ciria-Recasens M; Polino L; Gurt A; de la Torre R; Maldonado R; Monfort J;
    Aging (Albany NY); 2020 Oct; 12(20):19923-19937. PubMed ID: 33080571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathogenesis-directed therapy of 2019 novel coronavirus disease.
    Stratton CW; Tang YW; Lu H
    J Med Virol; 2021 Mar; 93(3):1320-1342. PubMed ID: 33073355
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vitamin D and survival in COVID-19 patients: A quasi-experimental study.
    Annweiler C; Hanotte B; Grandin de l'Eprevier C; Sabatier JM; Lafaie L; Célarier T
    J Steroid Biochem Mol Biol; 2020 Nov; 204():105771. PubMed ID: 33065275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Natalizumab versus fingolimod for patients with active relapsing-remitting multiple sclerosis: results from REVEAL, a prospective, randomised head-to-head study.
    Butzkueven H; Licata S; Jeffery D; Arnold DL; Filippi M; Geurts JJ; Santra S; Campbell N; Ho PR;
    BMJ Open; 2020 Oct; 10(10):e038861. PubMed ID: 33082194
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is the shielding effect of cholecalciferol in SARS CoV-2 infection dependable? An evidence based unraveling.
    Lahoor Basha S; Suresh S; Ashok Reddy VV; Surya Teja SP
    Clin Epidemiol Glob Health; 2021; 9():326-331. PubMed ID: 33102933
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vitamin D Update.
    Matsui MS
    Curr Dermatol Rep; 2020; 9(4):323-330. PubMed ID: 33078087
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Morphoproteomics Identifies the Vitamin D Receptor as a Potential Therapeutic Partner in Alveolar Pneumocytes for COVID-19 Infected Patients.
    Brown RE; Wolf DA; Tahseen D
    Ann Clin Lab Sci; 2020 Sep; 50(5):699-700. PubMed ID: 33067219
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 20.